Eighty-nine patients, ranging from 4 to 44 years, diagnosed with LCA or EOSRD caused by RPE65 biallelic mutation were included in clinical trials investigating the safety and efficacy of 3 types of vectors [15, 26, 32–34]. The gene discussed is RPE65; the disease is severe early-childhood-onset retinal dystrophy.